1ST.AX up 22% pre-market on ASX: top gainer watch at A$0.011

1ST.AX stock jumped 22.22% in pre-market trading on 19 Feb 2026, moving to A$0.011 on the ASX. Volume surged to 2,075,140 shares, three times the daily average. The move makes 1st Group Limited (1ST.AX) one of today’s top gainers in the Healthcare sector in Australia. We examine the drivers, the financial snapshot, and what our models forecast for near-term price action.

What moved 1ST.AX stock pre-market

The immediate trigger was a spike in buying interest at the open, lifting the price from A$0.009 to A$0.011. The one-day change is +22.22% and relative volume is 3.06, signalling outsized trade activity. There was no fresh earnings release. Market participants cited improved interest in healthcare marketplaces and SaaS listings as context for the trade. For company filings and broader market rules, see Nasdaq rule updates and global market flows source.

Financial snapshot and valuation for 1ST.AX stock

Key metrics: market cap A$15,586,889.00, EPS -0.01, and PE -1.10. Trailing revenue per share is A$0.0034 and book value per share is negative. Price averages are above recent means: 50-day average about A$0.009 and 200-day average about A$0.008. The company sits in Healthcare, Medical – Healthcare Information Services. Cash per share is A$0.0011, and current ratio is 0.83, indicating tight short-term liquidity.

Technical and trading flow for 1ST.AX stock

Price action shows a short-term breakout from recent averages. Day range was A$0.011 to A$0.011 with a year high of A$0.015 and year low of A$0.004. Average volume is 678,621; today’s 2,075,140 is a clear liquidity pick-up. Short-term traders should note low absolute price and wide percentage swings. Watch support near the year low and resistance near the year high for intraday signals.

Meyka AI grade and forecast for 1ST.AX stock

Meyka AI rates 1ST.AX with a score out of 100: 65.22 (Grade B) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a one-year price of A$0.00718, compared with the current A$0.011. That implies an expected change of -34.75% versus today’s price. Forecasts are model-based projections and not guarantees.

Price targets, analyst view and realistic scenarios for 1ST.AX stock

There is no formal consensus price target. Reasonable scenario-based targets are: base target A$0.015 (36.36% upside), optimistic A$0.020 (81.82% upside), and downside A$0.004 (year low). These targets reflect thin liquidity, negative EPS, and platform growth opportunities in telehealth and appointment marketplaces. Any change to contract wins or a funding update could alter the outlook rapidly.

Risks, sector context and trading strategy for 1ST.AX stock

Key risks include negative earnings, tight cash metrics, and long payables days. The Healthcare sector in Australia has underperformed YTD, with several large caps showing mixed flows. For traders, treat 1ST.AX as a high-volatility, small-cap healthcare play. Consider position sizing, limit orders, and quick profit targets rather than long duration holds. See broader market indices for context on investor flows source.

Final Thoughts

1ST.AX stock is a top pre-market gainer on 19 Feb 2026 after a 22.22% jump to A$0.011 on ASX. The volume surge and break above short-term averages mark a momentum event, but fundamentals remain weak. Meyka AI’s forecast model projects A$0.00718, implying -34.75% from the current price. That forecast and our B (65.22) grade reflect mixed signals: potential upside from marketplace growth, offset by negative EPS and tight liquidity. Traders should watch intraday liquidity and any company updates closely. For deeper company data, visit our Meyka stock page for 1ST.AX at Meyka 1ST.AX. Remember, forecasts are model-based projections and not guarantees. Use tight risk controls and size positions for this small-cap healthcare stock.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.